Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$10.3B
833M shares
52-week range
$11.36 – $15.67
21% from low
Exchange
NYSE
ADRC
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
www.drreddys.comNo one on the platform currently holds RDY.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 7,859,728 | $108.9M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-24 | $0.0834 | 2026-08-05 |
| 2025-07-25 | $0.0915 | 2025-08-06 |
| 2024-07-30 | $0.4762 | 2024-08-12 |
| Execution date | Ratio |
|---|---|
| 2024-11-05 | 5-for-1 |
| 2006-09-07 | 2-for-1 |
No one on the platform has traded RDY yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $347.3B | +0.6% | $43.17 | $36.74–$46.84 | 0.3× | 2 |
| 2028 | $387.9B | +11.7% | $56.62 | $46.06–$62.37 | 0.2× | 2 |
| 2029 | $426.9B | +10.1% | $70.11 | $65.89–$78.14 | 0.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-21 | $0.09 | $0.06 | -34.7% |
| 2026-05-11 | $0.09 | $0.06 | -33.3% |
| 2026-01-20 | $0.16 | $0.16 | +0.0% |
| 2025-10-24 | $0.19 | $0.19 | -1.4% |
| 2025-07-23 | $0.21 | $0.20 | -6.7% |
| 2025-05-09 | $0.21 | $0.22 | +4.0% |
| 2024-11-05 | $0.21 | $0.04 | -80.6% |
| 2024-07-27 | $0.19 | $0.20 | +4.0% |
| -0.13% |
| $10.6B |
| — |
| EXELExelixis, Inc. | $51.24 | +1.24% | $12.9B | — |
| NBIXNeurocrine Biosciences, Inc. | $152.72 | +1.26% | $15.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
📊 Today's Trade Ideas 1️⃣ $RDY Momentum Setup • 68% Entry: $11.74 - $11.97 Target: $12.51 Stop: $11.33 Risk: Medium 2️⃣ $JGRO Momentum Setup • 54% Entry: $92.74 - $93.80 Target: $98.80 Stop: $89.48 Risk: High 3️⃣ $HALO Watchlist Setup • 44% Entry: $80.44 - $81.19 Target: $85.69 Stop: $77.61 Risk: Low Not financial advice.
View on StockTwits ↗$RDY Biosimilars are a long-term growth area as expensive biologic drugs lose exclusivity...
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-7-22-dr-reddys-laboratories-limited-stock/ $RDY Dr. Reddy's Laboratories Earnings Transcr
View on StockTwits ↗$COYA my only ticker not seeing big green... weird seeing SP so heavily tied to $RDY .
View on StockTwits ↗$RDY Current Stock Price: $14.12 Contracts to trade: $15.0 RDY Jul 17 2026 Call Entry: $0.09 Exit: $0.13 ROI: 48% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$RDY: Dr. Reddy's launches its generic semaglutide injection in Canada https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260518061903RDY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
View on StockTwits ↗$RDY $NVO Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada "The launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company's readiness to serve Canadian patients Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada"
View on StockTwits ↗https://marketbeat.com/a/8654460/ $RDY Dr. Reddy's Laboratories Q4 Earnings Call Highlights
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-5-12-dr-reddys-laboratories-limited-stock/ $RDY Dr. Reddy's Laboratories Earnings Transcr
View on StockTwits ↗$RDY News: Dr. Reddy’s to sell Ozempic generics in Canada in days (RDY)
View on StockTwits ↗$RDY Share Price: $12.34 Contract Selected: Dec 18, 2026 $12.5 Calls Buy Zone: $2.68 – $3.31 Target Zone: $4.58 – $5.60 Potential Upside: 62% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$RDY Price: $13.14 (-0.68%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.88% RSI: 56.8 | Momentum: Moderate Volume: +21.1% vs avg Volatility: 1.96% Support: $12.77 | Resistance: $14.20 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.